Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not Improve OS or iDFS in High-Risk HR-positive, HER2-negative Primary Breast Cancer By Ogkologos - April 8, 2025 817 0 Facebook Twitter Google+ Pinterest WhatsApp Final survival results from the PENELOPE-B study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Routes to a healthier shopping journey – how your supermarket environment... April 19, 2023 Tips On Staying Cool During a Heat Wave June 30, 2021 EMA Recommends Extension of Therapeutic Indications for Durvalumab and Adopts a... December 23, 2022 Do Frequent Follow-Up Tests Benefit Colorectal Cancer Survivors? June 20, 2018 Load more HOT NEWS Olivia Newton-John Talks About Her Use Of Medical Cannabis During Cancer... Child With Cancer Becomes Honorary First Responder FDA Approves Darolutamide Tablets for Metastatic Hormone-Sensitive Prostate Cancer Boosting Dendritic Cells Helps the Immune System Find Pancreatic Cancer
